Skip to main content

Our Company

About Us

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and a product platform targeting immuno-inflammatory pathways.

Our Executive Team

We have the privilege to work as a team towards fulfillment of our mission to pioneer new innovations to treat autoimmune and inflammatory diseases and most importantly to make a difference in the lives of patients.

Scientific and Clinical Advisors

Our Partners

As Equillium was founded, the company acquired rights for developing and commercializing itolizumab in the U.S., Canada, Australia and New Zealand through an exclusive collaboration and license agreement with Biocon.

Biocon logo